Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy
This article was originally published in The Pink Sheet Daily
Japan's largest drug maker confirms Nycomed deal, which will double its European sales, jumpstart its emerging markets presence and provide a 30% revenue boost as key drug Actos faces patent expiry.
You may also be interested in...
Takeda’s expansion into emerging markets using its Nycomed acquisition have positioned it well in Russia and Brazil and given Japan’s largest drug maker a small but solid base in China, but its head of international operations says he’s in no rush to expand into India, given the fluid and complex nature of that market.
New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.
Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.